Navigation Links
Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease
Date:12/8/2010

eir exciting pharmacological chaperone approach to modify the progression of Parkinson's disease," said Dr. Chesselet. "Amicus' earlier compound partially reversed the motor deficits in our alpha-synuclein overexpression mouse model, and we are eager to test the improved compounds."

John F. Crowley, Chairman and CEO of Amicus Therapeutics stated, "We appreciate MJFF's backing of our pharmacological chaperone technology and believe this grant further demonstrates the strong scientific capabilities at Amicus.  We hope that these continued discoveries will translate into therapies for people living with Parkinson's disease."

About Pharmacological Chaperones

Pharmacological chaperones are orally-available small molecules that selectively bind and stabilize target proteins to facilitate proper folding, reduce premature degradation, and increase the efficiency of protein trafficking through the cell.  The use of pharmacological chaperones may be broadly applicable to diseases where an increase in the activity of a specific protein may provide therapeutic benefit.  

About Pharmacological Chaperones for Parkinson's Disease

Mutations in the GBA1 gene are the most common genetic risk factor known for Parkinson's disease.  Those at increased risk include individuals who inherit only one mutant copy of GBA1, while the other copy is normal.  GBA1 mutations reduce the activity of the lysosomal enzyme glucocerebrosidase (GCase), which leads to Gaucher disease when two mutant copies of the gene are inherited.  Increasing the activity of GCase in the brain with a small-molecule pharmacological chaperone may reduce the negative consequences of carrying GBA1 mutations.  Amicus and collaborators have previously  demonstrated that administration of the pharmacological chaperone AT2101 to mice that were genetically engineered to over-produce -synuclein increased the activi
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
2. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
3. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
4. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
5. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
6. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
7. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
8. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
9. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
10. Amicus Therapeutics Announces Closing of $18.5 Million Registered Direct Offering of Common Stock
11. Amicus Therapeutics Announces $18.5 Million Registered Direct Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
(Date:9/22/2014)... , September 22, 2014 ... September 25   The second edition of ... are excited to announce the final nominations for the ... announced on the evening of September 25 at The Taj Mahal Palace, ... from applicants based on a variety of qualitative and ...
(Date:9/22/2014)... 22, 2014 Decision Resources Group finds that by ... to be worth $2 billion (U.S. dollars), increasing at a ... five years (to 2018). This growth comes as ... 2013 and 4.9 percent expected over the next three to ... small but highly competitive. The pharmaceutical market is dominated by ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 2Recognising Impactful Healthcare Companies at VCCircle Healthcare Awards 2014 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3
... The U.S. Food and Drug Administration,s (FDA) ... decided today that it could not recommend approval ... the currently available data (13-3); but, voted unanimously ... a reader training program that demonstrates reader accuracy ...
... Medical Simulation Corporation (MSC) will highlight a ... providers at the 2011 International Meeting on Simulation ... MSC,s full-service simulation training and education services are ... all healthcare providers. MSC,s complete line of equipment ...
Cached Medicine Technology:Statement from Lilly and Avid on FDA Advisory Committee Recommendation for Amyvid™ (Florbetapir) NDA 2Medical Simulation Corporation to Feature Full Spectrum of Services and Simulation-Based Curriculum at the 11th Annual International Meeting on Simulation in Healthcare 2
(Date:9/22/2014)... On Tuesday, September 16th, 2014, at 8:00 p.m. ... “KC After Dark.” Hosted by top WRNW1 host, ... every Tuesday at 8:00 p.m. EST. WRNW1 had a promotion ... and because of the amazing turnout for their first show, ... 500 callers. , During this comical, yet professional show, ...
(Date:9/22/2014)... September 22, 2014 The Philadelphia 100, ... Greater Philadelphia region each year, is considered a hallmark ... manufacturer MK Precision is proud to announce it has ... MK Precision will attend the Philadelphia 100 ... the premiere business events of the year, as well ...
(Date:9/22/2014)... 2014 (HealthDay News) -- All sexually active women ... common sexually transmitted infections: chlamydia and gonorrhea, according ... Task Force. The task force noted ... 24 years of age and pregnant women. ... noticeable symptoms. As a result, many infections go ...
(Date:9/22/2014)... Amy Norton HealthDay Reporter ... may fare better when newborn intensive care units (NICU) set ... infants, a new study finds. Researchers at one children,s ... and were less distressed when their NICU switched from the ... findings, published online Sept. 22 in the journal Pediatrics ...
(Date:9/22/2014)... seems futuristic, if not impossible. But with a ... researchers at University of California, San Diego School ... an entire, functional eye a reality. , "A ... for vision restoration," said Jeffrey Goldberg, MD, PhD, ... at University of Pittsburg Medical Center and Boston ...
Breaking Medicine News(10 mins):Health News:The Women’s Radio Network, WRNW1’s First Evening Show a Huge Success 2Health News:MK Precision Announces Spot on Philadelphia 100 Fastest Growing Companies 2Health News:Screen Women for Chlamydia, Gonorrhea, Experts Say 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 2Health News:Newborn ICUs With Private Family Rooms Benefit Preemies: Study 3Health News:Looking ahead: Whole eye transplant under development 2
... The Autism Research Institute states that many of those ... appropriately diagnosed and treated may result in marked improvementATLANTA, ... every 20 seconds in the US. Autism is ... AIDS combined. The Federal Centers for Disease Control ...
... SANTA MONICA, Calif., April 6 Cord Blood America, Inc. ... preservation company ( http://www.cordblood-america.com ) ... to families nationwide and internationally, is pleased to announce that ... long term debt by approximately $750,000, or 12 percent. ...
... place in line at local emergency departments and ... has selected Trevelino/Keller Communications Group, Inc., one of ... launch the company nationally and build out its ... Alabama and Florida -- as it pursues national ...
... a systemic disease or an autoimmune disorder in which the ... of cells called the synovium that lines and lubricates the ... and crippling stiffness, particularly of the hands and feet. It ... mobility and quality of life. RA cannot be confirmed or ...
... solutions provider, is pleased to announce that its entire suite of ... , ... Charlotte, NC (PRWEB) April 6, 2009 -- IQMax, ... that its entire suite of healthcare solutions is available on Blackberry® ...
... high blood pressure and heart disease during a clinical trial for osteoarthritis. ... ... Company, a Bendigo based company who manufactures a topical pain relief lotion ... trial for their flagship product, Elmore Oil., , ,The trial was headed ...
Cached Medicine News:Health News:Alarming Rise in Autism Brings Hundreds of Parents, Researchers and Clinicians Together from Around the World to Atlanta April 17-19, 2009 2Health News:Cord Blood Announces $1.75 Million Reduction in Long Term Debt 2Health News:Imagine No More Waits for Emergency Room Care ... InQuickER Chooses Trevelino/Keller Communications to Launch First Service of Its Kind 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 2Health News:Rheumatoid Arthritis Therapeutics in Thailand 3Health News:IQMax Delivers Healthcare Solutions to Blackberry Devices 2Health News:Arthritis Trial Leads to Potential Cure for High Blood Pressure 2
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9CA Broth...
Form: Cream-colored powder Moisture: 10% Ash: 6.5% Gel Strength (1.5%): 550 950 gm/cm 2 Gel pH (1.5%): 6.0 7.5 Gel Point (1.5%): 34 38C Melting Point (1.5%): 84 88C Application: Bacterial ...
...
Medicine Products: